Published in Breast Cancer Res Treat on August 10, 2012
Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA. Breast Cancer Res (2015) 1.08
MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Breast Cancer Res (2015) 0.93
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer. Nat Commun (2016) 0.92
HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction. Sci Rep (2014) 0.84
ABCG2 is not able to catalyze glutathione efflux and does not contribute to GSH-dependent collateral sensitivity. Front Pharmacol (2013) 0.84
Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer. Breast Cancer Res Treat (2015) 0.82
Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer. Breast Cancer Res (2014) 0.79
Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway. J Cell Physiol (2014) 0.78
Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles. Cancer Res (2017) 0.75
Stress granule-associated protein G3BP2 regulates breast tumor initiation. Proc Natl Acad Sci U S A (2017) 0.75
Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer. Oncotarget (2016) 0.75
Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1. Int J Environ Res Public Health (2015) 0.75
Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer. Mol Cancer Ther (2015) 0.75
Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications. Int J Mol Sci (2017) 0.75
Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med (2009) 4.26
Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci U S A (2004) 3.07
Bach1 competes with Nrf2 leading to negative regulation of the antioxidant response element (ARE)-mediated NAD(P)H:quinone oxidoreductase 1 gene expression and induction in response to antioxidants. J Biol Chem (2005) 2.14
GSK-3beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2. J Biol Chem (2007) 2.14
Retracted Nuclear import and export signals in control of Nrf2. J Biol Chem (2005) 1.98
miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem (2011) 1.98
Retracted Prothymosin-alpha mediates nuclear import of the INrf2/Cul3 Rbx1 complex to degrade nuclear Nrf2. J Biol Chem (2009) 1.92
Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res (2005) 1.84
Retracted Phosphorylation of tyrosine 568 controls nuclear export of Nrf2. J Biol Chem (2006) 1.84
Retracted Src subfamily kinases regulate nuclear export and degradation of transcription factor Nrf2 to switch off Nrf2-mediated antioxidant activation of cytoprotective gene expression. J Biol Chem (2011) 1.82
Laminar flow induction of antioxidant response element-mediated genes in endothelial cells. A novel anti-inflammatory mechanism. J Biol Chem (2002) 1.75
Nrf2 signaling and cell survival. Toxicol Appl Pharmacol (2009) 1.72
Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther (2010) 1.70
BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res (2004) 1.69
An auto-regulatory loop between stress sensors INrf2 and Nrf2 controls their cellular abundance. J Biol Chem (2007) 1.63
Retracted Phosphorylation and dephosphorylation of tyrosine 141 regulate stability and degradation of INrf2: a novel mechanism in Nrf2 activation. J Biol Chem (2008) 1.61
Retracted Antioxidant-induced modification of INrf2 cysteine 151 and PKC-delta-mediated phosphorylation of Nrf2 serine 40 are both required for stabilization and nuclear translocation of Nrf2 and increased drug resistance. J Cell Sci (2009) 1.58
High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One (2010) 1.54
Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem (2012) 1.49
Myeloid sarcomas: a histologic, immunohistochemical, and cytogenetic study. Diagn Pathol (2007) 1.46
Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia. Cancer Res (2002) 1.45
The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene? FASEB J (2012) 1.37
Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol (2011) 1.36
Increasing national mastectomy rates for the treatment of early stage breast cancer. Ann Surg Oncol (2012) 1.35
Retracted NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53. Cancer Res (2007) 1.31
Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity. Clin Exp Metastasis (2008) 1.25
Nrf3 negatively regulates antioxidant-response element-mediated expression and antioxidant induction of NAD(P)H:quinone oxidoreductase1 gene. J Biol Chem (2004) 1.23
c-Maf negatively regulates ARE-mediated detoxifying enzyme genes expression and anti-oxidant induction. Oncogene (2002) 1.22
Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci U S A (2014) 1.18
Nrf2-induced antiapoptotic Bcl-xL protein enhances cell survival and drug resistance. Free Radic Biol Med (2012) 1.17
Lower induction of p53 and decreased apoptosis in NQO1-null mice lead to increased sensitivity to chemical-induced skin carcinogenesis. Cancer Res (2005) 1.13
Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. J Biol Chem (2002) 1.11
Antioxidant-induced phosphorylation of tyrosine 486 leads to rapid nuclear export of Bach1 that allows Nrf2 to bind to the antioxidant response element and activate defensive gene expression. J Biol Chem (2009) 1.11
NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. Biochem Pharmacol (2006) 1.09
Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res (2011) 1.09
Genetic susceptibility to benzene-induced toxicity: role of NADPH: quinone oxidoreductase-1. Cancer Res (2003) 1.07
Retracted Inhibitor of Nrf2 (INrf2 or Keap1) protein degrades Bcl-xL via phosphoglycerate mutase 5 and controls cellular apoptosis. J Biol Chem (2011) 1.07
Targeting abnormal DNA repair in therapy-resistant breast cancers. Mol Cancer Res (2011) 1.07
Therapeutic observations in MCF-7 aromatase xenografts. Clin Cancer Res (2005) 1.06
A Role for OCT4 in Tumor Initiation of Drug-Resistant Prostate Cancer Cells. Genes Cancer (2010) 1.06
Low and high dose UVB regulation of transcription factor NF-E2-related factor 2. Cancer Res (2006) 1.05
Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Invest New Drugs (2012) 1.05
Use of appropriate statistical methods while conducting a meta-analysis. Int J Stroke (2014) 1.05
Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test. Cytometry A (2014) 1.02
Model systems: mechanisms involved in the loss of sensitivity to letrozole. J Steroid Biochem Mol Biol (2005) 1.02
Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Mol Cancer Ther (2008) 0.99
BALT development and augmentation of hyperoxic lung injury in mice deficient in NQO1 and NQO2. Free Radic Biol Med (2006) 0.99
NAD(P)H quinone oxidoreductase 1 is essential for ozone-induced oxidative stress in mice and humans. Am J Respir Cell Mol Biol (2008) 0.99
Nuclear factor Nrf2 and antioxidant response element regulate NRH:quinone oxidoreductase 2 (NQO2) gene expression and antioxidant induction. Free Radic Biol Med (2005) 0.99
NQO1 and NQO2 regulation of humoral immunity and autoimmunity. J Biol Chem (2006) 0.99
Tyrosine phosphorylation controls nuclear export of Fyn, allowing Nrf2 activation of cytoprotective gene expression. FASEB J (2010) 0.98
Role of GRP58 in mitomycin C-induced DNA cross-linking. Cancer Res (2003) 0.98
Inactivation of the quinone oxidoreductases NQO1 and NQO2 strongly elevates the incidence and multiplicity of chemically induced skin tumors. Cancer Res (2010) 0.97
An autoregulatory loop between Nrf2 and Cul3-Rbx1 controls their cellular abundance. J Biol Chem (2010) 0.97
Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening. J Antimicrob Chemother (2009) 0.97
Pulmonary vascular permeability and ischemic injury in gelsolin-deficient mice. Am J Respir Cell Mol Biol (2003) 0.95
Deficiency of NRH:quinone oxidoreductase 2 increases susceptibility to 7,12-dimethylbenz(a)anthracene and benzo(a)pyrene-induced skin carcinogenesis. Cancer Res (2004) 0.94
GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells. BMC Cancer (2011) 0.94
The role of c-Jun phosphorylation in EpRE activation of phase II genes. Free Radic Biol Med (2009) 0.93
Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer. Mol Cancer Ther (2007) 0.93
A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors. Breast Cancer Res Treat (2013) 0.92
Challenges in the endocrine management of breast cancer. Breast (2003) 0.92
Aromatase inhibitors and breast cancer. Ann N Y Acad Sci (2009) 0.91
Disruption of NAD(P)H:quinone oxidoreductase 1 gene in mice leads to radiation-induced myeloproliferative disease. Cancer Res (2008) 0.90
Preclinical modeling of endocrine response and resistance: focus on aromatase inhibitors. Cancer (2008) 0.89
A physiological threshold for protection against menadione toxicity by human NAD(P)H:quinone oxidoreductase (NQO1) in Chinese hamster ovary (CHO) cells. Biochem Pharmacol (2002) 0.89
Sp3 repression of polymorphic human NRH:quinone oxidoreductase 2 gene promoter. Free Radic Biol Med (2004) 0.88
Nicotine promotes apoptosis resistance of breast cancer cells and enrichment of side population cells with cancer stem cell-like properties via a signaling cascade involving galectin-3, α9 nicotinic acetylcholine receptor and STAT3. Breast Cancer Res Treat (2014) 0.88
Zoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interaction. J Steroid Biochem Mol Biol (2012) 0.88
Retracted Hsp90 interaction with INrf2(Keap1) mediates stress-induced Nrf2 activation. J Biol Chem (2010) 0.88
Quinone oxidoreductases and vitamin K metabolism. Vitam Horm (2008) 0.87
Retracted Antioxidant-induced INrf2 (Keap1) tyrosine 85 phosphorylation controls the nuclear export and degradation of the INrf2-Cul3-Rbx1 complex to allow normal Nrf2 activation and repression. J Cell Sci (2012) 0.87
Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules. Antimicrob Agents Chemother (2013) 0.87
Quinone oxidoreductases in protection against myelogenous hyperplasia and benzene toxicity. Chem Biol Interact (2005) 0.87
Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. Mol Cancer Ther (2011) 0.87
Inhibition of oxygen-induced hypoxia-inducible factor-1alpha degradation unmasks estradiol induction of vascular endothelial growth factor expression in ECC-1 cancer cells in vitro. Endocrinology (2009) 0.86
New insight into the transcriptional regulation of vascular endothelial growth factor expression in the endometrium by estrogen and relaxin. Ann N Y Acad Sci (2005) 0.86
Deficiency of NRH:quinone oxidoreductase 2 differentially regulates TNF signaling in keratinocytes: up-regulation of apoptosis correlates with down-regulation of cell survival kinases. Cancer Res (2007) 0.86
Aromatase resistance mechanisms in model systems in vivo. J Steroid Biochem Mol Biol (2009) 0.86
HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2. Mol Cancer Ther (2013) 0.85
NRH:quinone oxidoreductase 2-deficient mice are highly susceptible to radiation-induced B-cell lymphomas. Clin Cancer Res (2009) 0.85
The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer. Urol Oncol (2008) 0.84
Association of NRH:quinone oxidoreductase 2 gene promoter polymorphism with higher gene expression and increased susceptibility to Parkinson's disease. J Gerontol A Biol Sci Med Sci (2008) 0.84
A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology. PLoS One (2013) 0.83
In vivo role of NAD(P)H:quinone oxidoreductase 1 in metabolic activation of mitomycin C and bone marrow cytotoxicity. Cancer Res (2007) 0.83
Persistent induction of hepatic and pulmonary phase II enzymes by 3-methylcholanthrene in rats. Toxicol Sci (2008) 0.83
Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses. J Antimicrob Chemother (2011) 0.83
Effects of NQO1 deficiency on levels of cyclopurines and other oxidative DNA lesions in liver and kidney of young mice. Int J Cancer (2004) 0.82
The aryl hydrocarbon receptor nuclear translocator (Arnt) is required for tumor initiation by benzo[a]pyrene. Carcinogenesis (2009) 0.82
Thioredoxin-like domains required for glucose regulatory protein 58 mediated reductive activation of mitomycin C leading to DNA cross-linking. Mol Cancer Ther (2007) 0.82
Retracted NAD(P)H:quinone oxidoreductase 1 (NQO1) competes with 20S proteasome for binding with C/EBPα leading to its stabilization and protection against radiation-induced myeloproliferative disease. J Biol Chem (2012) 0.82
Zoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-κB. Mol Cancer Ther (2013) 0.81